HOME >> MEDICINE >> NEWS
Common osteoporosis treatment may help men with prostate cancer suffering from bone loss

SAN FRANCISCO, Feb. 25 Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott. The study, abstract number 139, will be featured in a press program at the meeting, 7:30 a.m., Sunday, Feb. 26.

"In previous studies, we have determined that men who receive androgen deprivation therapy, a frequently used treatment for prostate cancer, suffer from severe drops in bone mass and are at an increased risk for fracture," said study principal investigator Susan Greenspan, M.D., professor of medicine, University of Pittsburgh and director, Osteoporosis Prevention and Treatment Center, UPMC. "In an attempt to mitigate these effects, we gave men using this therapy a once-weekly oral agent called alendronate that is commonly used to treat osteoporosis. We found that men who received it had significantly increased bone mass compared to those who did not receive the therapy."

The study included 112 men with prostate cancer with an average age of 71. After an average of two years androgen deprivation therapy for prostate cancer, only 9 percent of the men had normal bone mass, while 52 percent had low bone mass and 39 percent developed osteoporosis. To study the effect of alendronate on these men, they were randomized into two groups to receive either alendronate once a week through an orally administered pill or a placebo. At one year follow-up, bone mass in the spine and hip increased significantly in the men treated with alendronate, 4.9 percent and 2.1 percent respectively. By comparison, men in the placebo group had significant losses of bone mass in the spine and hip, 1.3 percent and .7 percent respectively. In addition, the therapy was well-tolerated and easily adm
'"/>


25-Feb-2006


Page: 1 2

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Common anesthetic may induce cell death, generation of Alzheimers-associated protein
4. Common blood pressure drug treats muscular dystrophy in mice
5. Common PTSD drug is no more effective than placebo
6. Common cold may be just a fingertip away due to environmental contamination
7. Commonwealth Fund commission says the US health care system needs thorough transformation
8. Commonly recommended sedative does not improve infant sleep
9. Common asthma inhaler causing deaths, researchers assert
10. Common painkillers associated with increased risk of first hospital admission for heart failure
11. Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome

Post Your Comments:
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 ... ... Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on two ... demonstration approved for a December 2015 launch; and Idaho’s partnership to revamp ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Roche under the trade name of ... the world. In Feb.26, 2010, it was approved by ... available in China all come ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
Cached News: